DOCSLIB.ORG

Cannabis Evidence Series, February 2, 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Evidence Series, February 2, 2017 Cannabis Evidence Series An Evidence Synthesis The Health Technology Assessment Unit, University of Calgary February 2, 2017 Cannabis Evidence Series February 2, 2017 Acknowledgements This report is authored by Laura E. Dowsett, Ally Memedovich, Hannah Holitzki, Laura Sevick, Sarah Ghali, Tamara McCarron, Stephanie Coward, Kelsey Brooks, Kai Lukowiak, Dolly Han, Vishva Danthurebandara, Diane Lorenzetti, Rebecca Haines-Saah, Tom Noseworthy, Eldon Spackman, and Fiona Clement on behalf of the HTA Unit at the University of Calgary. The authors declare no conflict of interests. This report was supported by a financial contribution from Alberta Health through the Alberta Health Technologies Decision Process, the Alberta model for health technology assessment (HTA) and policy analysis. The views expressed herein do not necessarily represent the official policy of Alberta Health. © 2016 Government of Alberta 2 Cannabis Evidence Series February 2, 2017 Issue Cannabis is the most widely used illicit drug in Canada; however, it is illegal to possess, produce or sell it 1. In 2015, the Liberal government of Canada formed a majority government and announced their plan to legalize cannabis. In June of 2016, a nine-member federal task force on cannabis was announced. The task force, chaired by Anne McLellan, includes representation from Quebec, British Columbia, Newfoundland and Labrador, Ontario, and Saskatchewan 2. Guided by this task force, cannabis legislation is expected to be introduced in 2017. Objective To inform Alberta’s response to the federal decision to legalize cannabis, the University of Calgary Health Technology Assessment (HTA) Unit is developing a series of evidence syntheses to support policy development by the Government of Alberta. This evidence series consists of five reports that address: Canadian Context Health effects and harms Medical cannabis Advertisement and communication regulations Experience with legalization among jurisdictions who have legalized including economic, sales and use regulations © 2016 Government of Alberta 3 Cannabis Evidence Series February 2, 2017 Executive Summary and Policy Messages © 2016 Government of Alberta 4 Cannabis Evidence Series February 2, 2017 Background Cannabis is the most widely used illicit drug in Canada; however, it is illegal to possess, produce, or sell cannabis 1. In 2015, the Government of Canada announced plans to legalize cannabis for non-medical use. In June of 2016, a nine-member federal task force on cannabis was established. The task force, chaired by Hon. Anne McLellan, includes representation from Quebec, British Columbia, Newfoundland and Labrador, Ontario, and Saskatchewan 2. The Task Force released its Framework for the Legalization & Regulation of Cannabis in Canada on November 30, 2016. Guided by input from this Task Force, cannabis legislation is expected to be introduced in 2017. To inform Alberta’s preparation for the federal decision to legalize cannabis, the University of Calgary Health Technology Assessment (HTA) Unit has completed a series of evidence syntheses to support policy development by the Government of Alberta. The five evidence syntheses focus on the following topics: 1. Current Canadian context 2. Health harms and effects 3. Medical cannabis 4. Advertising and communication 5. Experience with legalization The purpose of this current report is to highlight the key findings and gaps from these evidence syntheses emerging policy options. Summary of Topic 1: Current Context Cannabis sativa, also known as cannabis, cannabis, weed, pot, or bud, is a multi-use crop that has been cultivated by humans for thousands of years. Today, there are three varieties of cannabis, C. sativa, C. indica, and ‘hybrid strains’, each of which induce different psychological and physiological effects depending on which cannabinoids they contain 3. The two most notable cannabinoids commonly investigated for medicinal use are tetrahydrocannabinol (THC) and cannabidiol (CBD). There are three broad categories of regulation for the non-medical use of cannabis: criminalization, decriminalization and legalization. When cannabis is criminalized, it is regulated as an illegal substance; the purchasing, selling and use of cannabis is prohibited and enforced 4. © 2016 Government of Alberta 5 Cannabis Evidence Series February 2, 2017 Levers for enforcement may include fines, incarceration, and/or mandatory treatment 4. Individuals found possessing, using or selling cannabis will have a criminal record 4. In places where cannabis is decriminalized, it is still considered an illegal substance; however, penalties are non-criminal in nature for some or all offenses 4,5. Some countries that have decriminalized use have regulations on ages of use, what products may be used, how much cannabis may be possessed, and potency 4. Fines may be used as an enforcement lever, but are not related to a criminal record 4. Legalization refers to a regulatory approach where cannabis is identified as a legal substance for non-medical use under the law 4, and all legal prohibitions against it have been removed 5. Where cannabis is legal, it may be regulated by regional jurisdiction, the country, or it may be unregulated (free-market) 4. When regulated by regional jurisdiction or country, elements that may be regulated include: production, distribution, minimal age to purchase, possession limits, cultivation for personal use, and driving while under the influence. 4. International Context Internationally, there is a continuum of cannabis regulatory approaches from criminalization to decriminalization and legalization. The possession of non-medical cannabis is legal in Uruguay, eight American states and one American jurisdiction, including Washington State, Colorado, Oregon, Alaska, Washington D.C., California, Maine, Massachusetts, and Nevada, and has been decriminalized in 31 countries and 18 states. Cannabis continues to be included within the United Nations (UN) drug control regime. When any UN nation chooses to legalize cannabis, it violates international law. Accordingly, that country is required to formally withdraw from these treaties 6. Canadian Context Within Canada, medical use of cannabis became legal with the passing of the Marijuana Medical Access Regulation in 2001. However, non-medical use has remained illegal since it was added to the Opium and Narcotics Drug Act in 1923. The debate on legalizing, decriminalizing or maintaining the status quo of non-medical cannabis largely began in the 1960s. However, no significant steps were taken towards legalizing, until the current Liberal Party of Canada formed a majority Federal Government in 2015 and announced their plan to legalize cannabis. On June © 2016 Government of Alberta 6 Cannabis Evidence Series February 2, 2017 20th, 2016 a Federal Task Force on Cannabis chaired by Hon. Anne McLellan was struck with the purpose of collecting input on how to legalize non-medical cannabis. If the federal government decides to legalize cannabis, Canada would be the second country in the world to consider it a legal substance (Uruguay being the first). Although it is illegal, cannabis is a widely used substance in Canada. Nationally, 10.5% of Canadians self-report using cannabis within the last 12 months and 33.7% report lifetime use. In Alberta, 8.9% used cannabis within the last 12 months. Sixty-five percent of Canadians support legalization of cannabis; support is highest in British Columbia and lowest in Quebec. Individuals are more likely to support legalization if they have used cannabis in the past 12 months, are under 35 years old, are male, have an annual income over $80,000, and have a university degree. Most Canadians who support legalization for non-medical use say they do so because they do not believe alcohol, tobacco and cannabis are different, and because they do not think cannabis possession should be penalized with a criminal record. Those who do not support legalization feel primarily that we need to protect children and youth, are particularly concerned about driving while under the influence, and do not believe the Federal Government should be involved in decisions such as these. Summary of Topic 2: Health Effects and Harms There is a considerable amount of research on physical and mental health harms related to non-medical cannabis use; a review of the literature found 64 systematic reviews on health effects and harms related to cannabis. The evidence suggests that cannabis may be associated with harm to physical and mental health. Specifically, there is an association with an increased risk of: testicular cancer; increased risk of mental health problems (including psychosis, mania, relapse of psychosis or schizophrenia); and, poor outcomes during pregnancy, such as low birth- weight babies, birth complications, pulmonary dysfunction, neurocognitive brain changes and functional brain changes. There is inconclusive evidence on many harms such as brain changes, bladder, prostate, penile, cervical and childhood cancers, bone loss, atrial fibrillation, suicide, depression, anxiety, and all-cause mortality. There is evidence that cannabis does not increase the risk of arteritis, lung, and head and neck cancers. A systematic review on the effects of second-hand cannabis smoke found that inhalation of second- hand smoke can result in detectable cannabinoids and metabolites in blood and urine. © 2016 Government of Alberta 7 Cannabis Evidence Series February 2, 2017 Non-smokers may experience psychoactive effects when exposed
Load more

Recommended publications
  • Cannabis (Sub)Culture, the Subcultural Repository, and Networked Mediation
    SIMULATED SESSIONS: CANNABIS (SUB)CULTURE, THE SUBCULTURAL REPOSITORY, AND NETWORKED MEDIATION Nathan J. Micinski A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS May 2014 Committee: Ellen Berry, Advisor Rob Sloane © 2014 Nathan Micinski All Rights Reserved iii ABSTRACT Ellen Berry, Advisor Subcultural theory is traditionally rooted in notions of social deviance or resistance. The criteria for determining who or what qualifies as subcultures, and the most effective ways to study them, are based on these assumptions. This project seeks to address these traditional modes of studying subcultures and discover ways in which their modification may lead to new understandings and ways of studying subcultures in the contemporary moment. This will be done by suggesting a change in the criteria of examining subcultures from that of deviance or resistance to identification with a collection of images, symbols, rituals, and narratives. The importance of this distinction is the ability to utilize the insights that studying subcultures can offer while avoiding the faults inherent in speaking for or at a subculture rather than with or from it. Beyond addressing theoretical concerns, this thesis aims to apply notions of subcultural theory to study the online community of Reddit, in particular, a subset known as r/trees–a virtual repository for those images, symbols, rituals, and narratives of cannabis subculture. R/trees illustrates the life and vibrancy of a unique subcultural entity, which to this point has evaded a cultural studies analysis. To that end, this project advocates for the importance of the cultural studies approach to analyzing cannabis subculture and further, to insert the findings of this study into that gap in the literature.
    [Show full text]
  • Guide to Worker Safety and Health in the Marijuana Industry Marijuana Occupational Health and Safety Work Group January 2017
    Guide to Worker Safety and Health in the Marijuana Industry Marijuana Occupational Health and Safety Work Group January 2017 colorado.gov/cdphe/marijuana-occupational-safety-health Guide to Worker Safety and Health in the Marijuana Industry: 2017 About this guide This guide is intended to help assist employers in the marijuana industry build occupational safety and health programs. While the foundation of this guide includes existing Colorado state and federal regulations, it is not a comprehensive guide to all of the regulations pertaining to occupational safety and health. It should be noted that this guide does not present any new occupational safety and health regulations for the marijuana industry. Marijuana cultivators, extractors, labs and retailers are required to adhere to all regulations established by the Colorado Department of Revenue’s Marijuana Enforcement Division (MED) https://www.colorado.gov/pacific/enforcement/laws-constitution-statutes-and-regulations-marijuana- enforcement. The marijuana industry in Colorado falls under federal OSHA jurisdiction and businesses must comply with OSHA regulations and recordkeeping requirements. In addition to OSHA regulations, marijuana businesses are required to comply with other state regulations including Colorado labor laws, Colorado workers’ compensation laws, Colorado hazardous waste laws, Colorado Pesticide Applicator’s Act, local fire codes, and other regulations that are specific to employment and labor as well as the production of retail and medical marijuana. Guide to Worker Safety and Health in the Marijuana Industry: 2017 About the Colorado Marijuana Occupational Health and Safety Work Group The Colorado Marijuana Occupational Health and Safety Work Group is a multidisciplinary group that was convened to draw on expertise and experiences of many professionals in the Colorado community.
    [Show full text]
  • Cannabis in New Zealand Perceptions of Use, Users and Policy
    Cannabis in New Zealand perceptions of use, users and policy Geoff Noller A thesis submitted for the degree of Doctor of Philosophy at the University of Otago, Christchurch Aotearoa, New Zealand November 5, 2008 ABSTRACT Introduction Despite humanity’s lengthy relationship with psychoactive substances, their consumption in contemporary societies is perceived as highly problematic. Cannabis, the most commonly imbibed illicit psychotropic, has come to embody these concerns. Medical and scientific research informs notions of use and user, with these being further constructed in the public realm by law, the media and policy against a backdrop of health deficits and other harms including risk taking, criminality and deviance. With many studies drawing on clinical populations, e.g. high intensity users or those in treatment, a pathologized view of the user predominates. Where general population studies incorporate user data, these typically concentrate on the epidemiology of use: frequency, intensity, duration, and symptoms of abuse and dependence. This, however, tells us little about the meaning of use for users or why use continues despite universal official disapprobation. A lack of studies incorporating user perspectives thus ensures the limited focus of much present research and a policy accent on supply reduction at the expense of harm minimisation and safe use education. Those choosing to continue use are stigmatised as deviant or dependant. This has the effect of further bolstering enforcement, a strategy showing little evidence of efficacy. The present study sought a comparison between this dominant discourse on cannabis use and the perspectives of users, with a range of exploratory hypotheses being identified. Method Eighty cannabis-using respondents participated in open-ended face-to-face interviews, of which seventy-six successfully completed a follow-up questionnaire.
    [Show full text]
  • Conference Agenda 74Th Annual Congress of the International
    74th Annual Congress of the International Institute of Public Finance - ConfTool Pr... Page 1 of 83 Conference Agenda 74th Annual Congress of the International Institute of Public Finance Date: Monday, 20/Aug/2018 3:30pm - 6:00pm Registration (also open on congress days from 8 am on) 3:30pm - 6:30pm IIPF Board of Management Meeting I (for Board only) Room A32, Main building 7:30pm - 9:30pm IIPF Board of Management Dinner (on invitation only) https://www.conftool.pro/iipf2018/index.php?page=browseSessions&print=yes&do... 04.09.2018 74th Annual Congress of the International Institute of Public Finance - ConfTool Pr... Page 2 of 83 Date: Tuesday, 21/Aug/2018 9:00am - 9:30am Opening Ceremony Main auditorium (Juhlasali), Main building 9:30am - 10:30am Plenary I: Keynote Lecture: Uta Schönberg (University College London) on "The Impact Main auditorium of Immigration on Regions and Workers" Session Chair: Wojciech Kopczuk, Columbia University (Juhlasali), Main building 10:30am - 11:00am Coffee Break 11:00am - 1:00pm A01: Firm Taxation Main auditorium (Juhlasali), Main building 11:00am - 11:30am Efficiency and the Taxation of Bank Profit Motohiro Sato1, Robin Boadway2, Jean-Francois Tremblay3 1Hitotsubashi University; 2Queen's University; 3University of Ottawa This paper explores the effect of the taxation of profits of banks and other financial intermediaries in a setting in which intermediation is inefficient. The inefficiencies arise from imperfect screening of lenders, which tends to limit lending, and government provision of deposit insurance, which encourages excessive lending. Three sorts of financial profit tax regimes are considered: R+F cash-flow taxation, standard corporate income taxation, and financial activities taxation.
    [Show full text]
  • Worldwide Estate and Inheritance Tax Guide
    Worldwide Estate and Inheritance Tax Guide 2021 Preface he Worldwide Estate and Inheritance trusts and foundations, settlements, Tax Guide 2021 (WEITG) is succession, statutory and forced heirship, published by the EY Private Client matrimonial regimes, testamentary Services network, which comprises documents and intestacy rules, and estate Tprofessionals from EY member tax treaty partners. The “Inheritance and firms. gift taxes at a glance” table on page 490 The 2021 edition summarizes the gift, highlights inheritance and gift taxes in all estate and inheritance tax systems 44 jurisdictions and territories. and describes wealth transfer planning For the reader’s reference, the names and considerations in 44 jurisdictions and symbols of the foreign currencies that are territories. It is relevant to the owners of mentioned in the guide are listed at the end family businesses and private companies, of the publication. managers of private capital enterprises, This publication should not be regarded executives of multinational companies and as offering a complete explanation of the other entrepreneurial and internationally tax matters referred to and is subject to mobile high-net-worth individuals. changes in the law and other applicable The content is based on information current rules. Local publications of a more detailed as of February 2021, unless otherwise nature are frequently available. Readers indicated in the text of the chapter. are advised to consult their local EY professionals for further information. Tax information The WEITG is published alongside three The chapters in the WEITG provide companion guides on broad-based taxes: information on the taxation of the the Worldwide Corporate Tax Guide, the accumulation and transfer of wealth (e.g., Worldwide Personal Tax and Immigration by gift, trust, bequest or inheritance) in Guide and the Worldwide VAT, GST and each jurisdiction, including sections on Sales Tax Guide.
    [Show full text]
  • The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I
    STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I. Giancaspro, Nam-Cheol Kim, Jaap Venema, Susan de Mars, Jennifer Devine, Carlos Celestino, Christine E. Feaster, Ben A. Firschein, Mary S. Waddell, Stephen M. Gardner, and Earl Jones Jr.a ABSTRACT This Stimuli article analyzes the need for public quality standards for medical cannabis (defined herein as marijuana used for medical purposes under state laws) and the potential role of the U.S. Pharmacopeial Convention (USP) in addressing that need.1 Following legalization of the medical use of cannabis in several U.S. states and internationally, USP has received requests to investigate the advisability and feasibility of developing quality standards for medical cannabis. Development of quality standards for medical cannabis requires consideration of a wide range of scientific, legal, and policy issues that reach far beyond its classification as a botanical drug or herbal medicine. This article discusses the current regulatory and scientific landscape regarding medical cannabis, identifies issues related to the lack of quality standards for medical cannabis, and explores potential options for developing quality standards. USP seeks input from stakeholders on whether USP should proceed with development of quality standards for medical cannabis and if so, what approaches should be utilized to establish such standards. LEGAL AND REGULATORY LANDSCAPE The federal and state regulatory environment surrounding the medical use of cannabis involves many federal agencies and various different state laws. The evolving legal environment is an important consideration when evaluating the advisability and feasibility of USP developing a public standard for cannabis.
    [Show full text]
  • TY18:Layout 1 17/08/09 16:06 Pagina 1 TY18:Layout 1 17/08/09 16:06 Pagina 2 TY18:Layout 1 17/08/09 16:06 Pagina 3 TY18:Layout 1 17/08/09 16:06 Pagina 4
    TY18:Layout 1 17/08/09 16:06 Pagina 1 TY18:Layout 1 17/08/09 16:06 Pagina 2 TY18:Layout 1 17/08/09 16:06 Pagina 3 TY18:Layout 1 17/08/09 16:06 Pagina 4 Publisher/ Editor in Chief Marco Renda [email protected] Assistant to Editor Jef Tek [email protected] Copy Editor Aendrew Rininsland [email protected] Magazine design & layout Ivan Art [email protected] Director of Sales & Marketing Michelle Rainey [email protected] Technical Writer Ally a.k.a Pflover [email protected] Q&A Advisor Shantibaba [email protected] Text & photography Contributors Marco Renda, Ændrew Rininsland, Ivan Art, Michelle Rainey, Otto Snow, PFlover, Jef Tek, Shantibaba, Jerry B., Soma, Jay Generation, Harry Resin, Dr Dog, Chris Thompson, Jeremy Norrie, Keith Fagin, John (Shiva), Lara Lesack, Richard Owl Mirror, Suggarpaw, British Hempire, Jackie Sutton, Salvatore Messina HD., David B. Allen M.D., Hashmasta-Kut, Ale Keppel, Gregorio “Goyo” Fernandez Cover Pic `Mr Nice Critical Mass flower at 6 weeks` by Gregorio Fernandez “Goyo” for Mr. Nice Seedbank Submissions [email protected] Treating Yourself 250 The East Mall, P.O. Box 36531 Etobicoke, Ontario M9B 3Y8 Canada T: + 416 620 1951 F: +416 620 0698 Printed in Canada 4 - Treating Yourself, Issue 18- 2009 TY18:Layout 1 17/08/09 16:06 Pagina 5 Marco’s Editorial Well I have to say issue number 17 certainly caused a lot of controversy, especially surrounding the Dr Frankenbeanstien article. Both Sam The Skunkman and Ed Rosenthal contacted me regarding this. I offered them both the chance to rebut what was published, but they declined to do so.
    [Show full text]
  • Management's Discussion and Analysis of Financial Condition and Results of Operations ("Md&A")
    INDIVA LIMITED MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2019 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") The following is a discussion and analysis of the financial condition and results of operations of Indiva Limited ("Indiva" or the "Company") for the three and nine month periods ended September 30, 2019. This MD&A should be read in conjunction with the Company's condensed consolidated interim financial statements and accompanying notes for the three and nine month periods ended September 30, 2019 and 2018 (the "Interim Financial Statements"). All amounts in the MD&A are in Canadian dollars unless indicated otherwise. The Company's accounting policies are in accordance with International Financial Reporting Standards (“IFRS”). The Company’s continuous disclosure documents are available on SEDAR at www.sedar.com. Indiva does not engage in any U.S. marijuana-related activities as defined in CSA Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities dated February 8, 2018 (the "CSA Notice"). While the Company has partnered with U.S.-based companies, these entities are not engaged in the cultivation, possession or distribution of marijuana. Instead, the Company has partnered with U.S.-based companies which develop and licence intellectual property and copyright branding to the cannabis market, and do not engage in 'plant-touching' activities. The effective date of this MD&A is November 29, 2019. FORWARD-LOOKING STATEMENTS This MD&A includes certain “forward-looking statements” or “forward-looking information” within the meaning of applicable Canadian securities legislation that are based upon current expectations, estimates, projections, assumptions and views of future events of management at the date hereof, and which involve risks and uncertainties associated with our business and the environment in which the business operates.
    [Show full text]
  • A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation
    A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation February 2020 Massachusetts Cannabis Control Commission: Steven J. Hoffman, Chairman Kay Doyle, Commissioner Jennifer Flanagan, Commissioner Britte McBride, Commissioner Shaleen Title, Commissioner Shawn Collins, Executive Director Prepared by the Massachusetts Cannabis Control Commission Research and Information Technology Departments: Samantha M. Doonan, BA, Research Analyst David McKenna, PhD, Chief Technology Officer Julie K. Johnson, PhD, Director of Research Acknowledgements External Collaborators Alexandra F. Kritikos, MA, Brandeis University Cannabis Control Commission Communications Cedric Sinclair, Director of Communications Maryalice Gill, Press Secretary Kirsten Swenson, Communications Specialist Management Alisa Stack, Chief Operating Officer Erika Scibelli, Chief of Staff Legal Christine Baily, General Counsel Allie DeAngelis, Associate General Counsel Enforcement and Licensing Yaw Gyebi, Chief of Enforcement Paul Payer, Enforcement Counsel Kyle Potvin, Director of Licensing Patrick Beyea, Director of Investigations Derek Chamberlin, Licensing Analyst Anne DiMare, Licensing Specialist Government Affairs David Lakeman, Director of Government Affairs 2 Suggested bibliographic reference format: Doonan SM., McKenna, D., Johnson JK., (2020, February). A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry— A Report to the Massachusetts Legislature. Boston, MA: Massachusetts Cannabis
    [Show full text]
  • Manifiesto Internacional OMS Cannabis Traducido 1:12
    Naciones Unidas E/CN.7/2020/NGO/7 Distr.: General Consejo Ecónomico y Social 25 November 2020 English only Comisión en drogas narcóticas Reanudada la sexagésimo tercera sesión Vienna, 2–4 diciembre 2020 Item 5 de la agenda provisional* Implementación de tratados de control de drogas internacionales Declaración presentada por la coalición europea por la justicia y políticas de drogas eficaces, una organización no gubernamental reconocida como entidad consultiva por el Consejo Social y Económico El Secretario-General ha recibido el siguiente manifiesto, el cual está siendo circulado de acuardo a los párrafos 36 y 37 de la resolución 1996/31 del Consejo Económico y Social __________________ * E/CN.7/2020/1/Add.1. ** Issued without formal editing. V.20-06992 (E) 261120 291120 *2006992* E/CN.7/2020/NGO/7 Manifiesto Apoya el acceso de pacientes a su medicina, ¡vota que sí! La cannabis ha sido una medicina convencional desde el amanecer de la civilización. En 1902 y 1929 las medicinas cannábicas fueron discutidas en la Conferencia Internacional por la Unificación de las Fórmulas Farmacopeicas para Drogas Potentes, la cual proporcionó pautas para armonizar las medicinas de cannabis y proveer a pacientes de drogas seguras y estandarizadas para sus tratamientos. Para este tiempo la cannabis ya era bastante aceptada en la práctica clínica y había sido reportada en las Farmacopeas de Austria, Bélgica, Francia, Hungaria, Italia, Japón, Holanda, Suiza, Reino Unido, Estados Unidos de América, así como en México y España. En 1958, las Naciones Unidas reportaron que la cannabis estaba también en las Farmacopeas de Argentina, Brazil, China, Egypt, Finland, India, Portugal, Romania, la URSS, y Venezuela.(2) Muchas preparacionas cannábicas están en textos ancestrales que componen la Farmacopea Ayurvédica (Charaka Samhita, Sushruta Samhita, Shargandhara Samhita) y en las Farmacopeas Mediterráneas de Umdat at-tabîb, Jami' al-mufradat, Hadîqat al-azhâr or Tuhfat al-ahbâb.
    [Show full text]
  • Annual Information Form
    CRONOS GROUP INC. ANNUAL INFORMATION FORM For the year ended December 31, 2018 DATED: March 25, 2019 TABLE OF CONTENTS GENERAL MATTERS ............................................................................................................................................... 3 FORWARD LOOKING INFORMATION ............................................................................................................... 3 CORPORATE STRUCTURE .................................................................................................................................... 6 GENERAL DEVELOPMENT OF THE BUSINESS ............................................................................................... 7 DESCRIPTION OF THE BUSINESS ..................................................................................................................... 13 ALTRIA STRATEGIC INVESTMENT ................................................................................................................. 39 RISK FACTORS ....................................................................................................................................................... 43 DIVIDENDS AND DISTRIBUTIONS ..................................................................................................................... 76 CAPITAL STRUCTURE .......................................................................................................................................... 76 MARKET FOR SECURITIES ................................................................................................................................
    [Show full text]
  • Cannabis Legalisation and Regulations in Canada
    CANNABIS LEGALISATION AND REGULATIONS IN CANADA BACKGROUND AND CHALLENGES IVANA OBRADOVIC MEMO NO. 2018-04 SAINT-DENIS, 11 OCTOBER 2018 OVERVIEW Following Uruguay in 2013, Canada is the second country in the world – the first in G7 – that has officially legalised the production, distribution and possession of cannabis for recreational use. Starting October 17, 2018, Canadian adults have been legally able to purchase recreational cannabis produced under licence, to possess up to 30 grams of cannabis and, in most provinces, to grow up to four cannabis plants at home. Canada is the first federal state to propose a decentralised model for the regulation of cannabis. The federal Cannabis Act has introduced an approach focused on public health and youth safety: it creates a strict legal framework to control the production, distribution, sales and possession of cannabis throughout Canada. Federal, provincial and territorial governments share responsibility for overseeing the cannabis regulation system. Conspicuously, provinces and territories have had to figure out their own regulation systems for the distribution Introduction 2 and sale of cannabis and all related safety measures Why legalisation? Context, dynamic and objectives of the reform 2 (for the minimum legal age, quantities and place Context and dynamic of the reform 2 of purchase or use, etc.), whereas municipalities Situational analysis of substance use 2 have the possibility to control use at local level, History of drug reforms 3 even though it remains illegal to transport cannabis A political and electoral argument 3 outside Canadian borders (regardless of quantity). Regain control of the medical cannabis market 5 Eradicating the black market 6 The implementation of this reform involves various Sizeable financial interests 6 jurisdiction levels and diverse regulation systems Legalisation for greater control: the challenge of regulation 7 across the country.
    [Show full text]